Maud Ngo‐Camus

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 747 citations

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti et al. · Clinical Cancer Research · 2019 · 162 citations · Full text

Trypan Blue Dye Enters Viable Cells Incubated with the Pore-Forming Toxin HlyII of Bacillus cereus

Seav‐Ly Tran, Andrea Puhar, Maud Ngo‐Camus et al. · PLoS ONE · 2011 · 134 citations · Full text

Microbial Toxin, Toxinology, Virulence Factor +13

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Emma Pailler, Nathalie Auger, Colin R. Lindsay et al. · Annals of Oncology · 2015 · 117 citations · Full text

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Emma Pailler, Vincent Faugeroux, Marianne Oulhen et al. · Clinical Cancer Research · 2019 · 116 citations · Full text